Publications by authors named "J S Sabari"
Article Synopsis
- Scientists found that using two medications together, one that stops cancer and another that helps blood vessels, can help people with a certain type of lung cancer live longer without their cancer getting worse.
- They ran a study (called the RAMOSE trial) comparing one medication plus the blood vessel helper to just the medication alone.
- The results showed that people taking both medications had better outcomes, living longer without cancer progression, even though both groups experienced side effects from the treatments.
Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers.
View Article and Find Full Text PDFArticle Synopsis
- A Phase III study tested the efficacy of subcutaneous versus intravenous amivantamab for patients with advanced non-small cell lung cancer (NSCLC) who had progression after prior treatments.
- Results showed that the subcutaneous form maintained efficacy, with fewer side effects and a significantly longer overall survival, while also being more convenient to administer.
- Patients receiving subcutaneous amivantamab had less infusion-related reactions and faster administration times, with 85% finding the treatment convenient compared to only 35% in the intravenous group.
Unlabelled: Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review.
View Article and Find Full Text PDF